 NEW YORK, July 7, 2021 PRNewswire -- Seelos Therapeutics, Inc. Nasdaq: SEEL, a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced positive in vivo data demonstrating down-regulation of SNCA mRNA and protein-expression from a study of SLS-004 in an in-vivo rodent model utilizing CRISPR-dCas9 gene therapy technology. A single dose of SLS-004 produced a therapeutically desirable 27 reduction on SNCA mRNA and a 40 reduction in SNCA protein expression. 